Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.09|
|52 Week High||US$0.87|
|52 Week Low||US$4.56|
|1 Month Change||0.48%|
|3 Month Change||-45.29%|
|1 Year Change||109.00%|
|3 Year Change||22.22%|
|5 Year Change||-77.88%|
|Change since IPO||-86.07%|
Recent News & Updates
|CTXR||US Pharmaceuticals||US Market|
Return vs Industry: CTXR exceeded the US Pharmaceuticals industry which returned 14.3% over the past year.
Return vs Market: CTXR exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: CTXR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CTXR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing four proprietary products, including Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Citius Pharmaceuticals Fundamentals Summary
|CTXR fundamental statistics|
Is CTXR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTXR income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||0.00%|
How did CTXR perform over the long term?See historical performance and comparison
Is Citius Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CTXR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CTXR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CTXR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTXR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTXR is good value based on its PB Ratio (2.2x) compared to the US Pharmaceuticals industry average (3.2x).
How is Citius Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CTXR's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if CTXR's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CTXR's revenue (256.9% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: CTXR's revenue (256.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CTXR's Return on Equity is forecast to be high in 3 years time
How has Citius Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTXR is currently unprofitable.
Growing Profit Margin: CTXR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CTXR is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare CTXR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CTXR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: CTXR has a negative Return on Equity (-16.18%), as it is currently unprofitable.
How is Citius Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CTXR's short term assets ($116.9M) exceed its short term liabilities ($3.6M).
Long Term Liabilities: CTXR's short term assets ($116.9M) exceed its long term liabilities ($5.7M).
Debt to Equity History and Analysis
Debt Level: CTXR's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: CTXR's debt to equity ratio has reduced from 1% to 0.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CTXR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CTXR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 30% each year
What is Citius Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTXR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTXR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTXR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTXR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTXR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Myron Holubiak (74 yo)
Mr. Myron Z. Holubiak has been the Chief Executive Officer and President of Citius Pharmaceuticals, Inc. since March 30, 2016 and has been its Director since October 1, 2015. Mr. Holubiak served as an Advi...
CEO Compensation Analysis
Compensation vs Market: Myron's total compensation ($USD875.04K) is below average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Myron's compensation has increased whilst the company is unprofitable.
Experienced Management: CTXR's management team is considered experienced (4.7 years average tenure).
Experienced Board: CTXR's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 163.1%.
Citius Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Citius Pharmaceuticals, Inc.
- Ticker: CTXR
- Exchange: NasdaqCM
- Founded: 2007
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$305.097m
- Shares outstanding: 145.98m
- Website: https://www.citiuspharma.com
Number of Employees
- Citius Pharmaceuticals, Inc.
- 11 Commerce Drive
- First Floor
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 22:06|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.